Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-363856 Physical Dependence in Schizophrenia
NCT05848700Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jun 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing SEP-363856 with Placebo (2 arms). Primary endpoint: Maximum change from steady-state baseline in the Physician Withdrawal Checklist (PWC-20) Total Score up to 10 weeks. Started Jun 2023; status: completed.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05848700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05848700.